-+ 0.00%
-+ 0.00%
-+ 0.00%

Changes in Hong Kong stocks | Lee's Pharmaceuticals (00950) rose more than 2%, and the subsidiary plans to acquire an automated heating module assembly line for up to US$76.684 million

Zhitongcaijing·11/20/2026 02:57:01
Listen to the news

The Zhitong Finance App learned that Lee's Pharmaceuticals (00950) rose more than 2%. As of press release, it had risen 2% to HK$1.02, with a turnover of HK$295,800.

According to the news, Lee's Pharmaceutical Co., Ltd. announced that on November 18, 2026 (after the transaction period), the buyer (an indirect wholly-owned subsidiary of the company) placed a purchase order with the seller to purchase the equipment, at a maximum cost of US$76.684 million (equivalent to about HK$598.14 million). The purchased equipment is a custom-designed automated heating component assembly line to manufacture heating components as components of Staccato® devices. The system integrates robot operating procedures to produce assembled products.

The Group is mainly engaged in drug development, manufacturing and commercialization business in the People's Republic of China (China) and international markets. The acquired equipment will enhance the Group's manufacturing capacity for heating components used in the production of Staccato® products through the acquisition of a highly automated assembly and testing line. The new production line is expected to increase production capacity, improve manufacturing efficiency, reduce reliance on manual procedures, and support the Group's future business growth and commercialization plans. The directors believe that the acquisition of this production line is in line with the Group's business strategy and will strengthen its production infrastructure and operating capacity.